|
I read the posts about this question (which are pretty much on the next page now). I know Iressa is in clinical trial to see if it can be used to restore tamoxifen's efficacy. I chose to quit tamoxifen and am considering the alternatives.
What I don't understand is at what point does the manufacturer have to start putting a warning about this question on their package insert?
None of my doctors mentioned the question to me. I had to take the information to my internist, and he talked with my oncologist about it. So far the only feedback I have received is that "Well, women are now generally being taken off tamoxifen after 2 years and put on an aromatase inhibitor, and you are almost at 2 years, so if you want to switch, it is okay."
Uhhhh.... if they think the combination of HER2+ and AIB1 is more likely than not to be dangerous in combination with tamoxifen, shouldn't they be testing women to see which ones are HER2+ and have AIB1?
Am I being dense?? Somebody help me out? Why does a HER2+ bc patient have to be the one to figure out that this question is out there? (I may be naive but I thought the whole idea of doing research was to help US out....)????
|
Threaded Mode